Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jos, Lommerse"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1092-1106 (2021)
Abstract Pharmacometric models can enhance clinical decision making, with covariates exposing potential contributions to variability of subpopulation characteristics, for example, demographics or disease status. Intuitive visualization of models with
Externí odkaz:
https://doaj.org/article/c21fd9582c8f4d6bb77d5556f2d45d1d
Autor:
Brian M. Maas, Jos Lommerse, Nele Plock, Radha A. Railkar, S.Y. Amy Cheung, Luzelena Caro, Jingxian Chen, Wen Liu, Ying Zhang, Qinlei Huang, Wei Gao, Li Qin, Jie Meng, Han Witjes, Emilie Schindler, Benjamin Guiastrennec, Francesco Bellanti, Daniel S. Spellman, Brad Roadcap, Mariya Kalinova, Juin Fok-Seang, Andrew P. Catchpole, Amy S. Espeseth, S. Aubrey Stoch, Eseng Lai, Kalpit A. Vora, Antonios O. Aliprantis, Jeffrey R. Sachs
Publikováno v:
EBioMedicine, Vol 73, Iss , Pp 103651- (2021)
Background: Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validat
Externí odkaz:
https://doaj.org/article/29110f874edd46dea00e331b42ac8484
Autor:
Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P. Acosta, Larissa Wenning, Sharon Nachman, Anne Chain
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 643-653 (2019)
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth des
Externí odkaz:
https://doaj.org/article/e0b66d5f0a014bd788ec368d457eb18d
Autor:
Anne Chain, Edward P. Acosta, Hedy Teppler, Mark Mirochnick, Betsy Smith, Jos Lommerse, Edmund V. Capparelli, Diana F Clarke
Publikováno v:
J Acquir Immune Defic Syndr
BACKGROUND: Population modeling and simulations can be used to facilitate the conduct of Phase I studies to develop safe and effective dosing regimens in neonates. SETTING: P1110 is an international, multicenter trial to determine safe and effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c31ca75deed1edf4e1342383719a381
https://doi.org/10.1097/qai.0000000000002149
https://doi.org/10.1097/qai.0000000000002149
Autor:
Henri Merdjan, Han Witjes, Anne Chain, Sharon Nachman, Hedy Teppler, Edward P. Acosta, Mark Mirochnick, Jos Lommerse, Thomas Kerbusch, Larissa Wenning, Diana F Clarke
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 643-653 (2019)
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 643-653 (2019)
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68cbdb82d8456af6f8e922f9a15407ca
https://doi.org/10.1002/psp4.12443
https://doi.org/10.1002/psp4.12443
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Pharmacometric models can enhance clinical decision making, with covariates exposing potential contributions to variability of subpopulation characteristics, for example, demographics or disease status. Intuitive visualization of models with multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e381a9e21bdc106caee5a83829646a9
https://pubmed.ncbi.nlm.nih.gov/34242494
https://pubmed.ncbi.nlm.nih.gov/34242494
Autor:
Nele Plock, Jos Lommerse, Brian M Maas, Jingxian Chen, Francesco Bellanti, Li Qin, Han Witjes, Philippe Pierrillas, Radha Railkar, Antonios O Aliprantis, Kalpit A Vora, Wei Gao, Luzelena Caro, S Y Amy Cheung, Jeffrey R Sachs
Publikováno v:
Open Forum Infectious Diseases. 8:S597-S598
Background MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody under development to prevent RSV infection in infants. A model-based meta-analysis (MBMA) describing the relationship between RSV serum neutrali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5a506a56ab48c3064544351f5d09d28
https://doi.org/10.1093/ofid/ofab466.1207
https://doi.org/10.1093/ofid/ofab466.1207
Autor:
Hedy Teppler, Stephanie Popson, Rohan Hazra, Yvonne J. Bryson, Impaact P s Protocol Team, Mae Cababasay, Kat Calabrese, Bobbie Graham, Jos Lommerse, Anne Chain, Edward P. Acosta, Diana F Clarke, Jiajia Wang, Stephen A. Spector, Mark Mirochnick, Betsy Smith
Publikováno v:
J Acquir Immune Defic Syndr
Background Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor available in a granule formulation suitable for use in neonates and young
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e3f781bc8c671ca77a5a9da7a9d7827
https://europepmc.org/articles/PMC7144886/
https://europepmc.org/articles/PMC7144886/
Autor:
Francesco Bellanti, Antonios O. Aliprantis, Juin Fok-Seang, Wen Liu, Jeffrey R. Sachs, Radha Railkar, Brad Roadcap, Kalpit A. Vora, Qinlei Huang, Li Qin, Nele Plock, W. Gao, Eseng Lai, Daniel S. Spellman, Jingxian Chen, Andrew P. Catchpole, Emilie Schindler, Mariya Kalinova, Amy S. Espeseth, Jie Meng, S. Y. Amy Cheung, Luzelena Caro, S. Aubrey Stoch, Benjamin Guiastrennec, Jos Lommerse, Brian M. Maas, Ying Zhang, Han Witjes
Publikováno v:
EBioMedicine, Vol 73, Iss, Pp 103651-(2021)
EBioMedicine
EBioMedicine
Background Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::979efaad60d5195380f7df59609ee178
https://doi.org/10.1016/j.ebiom.2021.103651
https://doi.org/10.1016/j.ebiom.2021.103651
Autor:
Arthur Oubrie, Carsten Schultz-Fademrecht, Vera de Kimpe, Bas van de Kar, Tjeerd Barf, Bert Kazemier, Niels Hoogenboom, Rianne Goorden, Judith Borsboom, Edwin de Zwart, Allard Kaptein, Michiel Scheffers, Jos Lommerse, Jeroen A.D.M. de Roos, Ruud van der Heijden, Maaike van Hoek
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(1)
Optimization of our previously described pyrrolopiperidone series led to the identification of a new benzamide sub-series, which exhibits consistently high potency in biochemical and cell-based assays throughout the series. Strong inhibition of LPS-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f7a874ec708632ed3e0fca030302d8
https://pubmed.ncbi.nlm.nih.gov/22119462
https://pubmed.ncbi.nlm.nih.gov/22119462